|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4B
|
|
pubmed:dateCreated |
2007-8-15
|
|
pubmed:abstractText |
Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it should be noted patients had been heavily pretreated with anthracyclines and taxanes. Our aim was to evaluate whether combination treatment would increase tumor growth inhibition and survival in a breast cancer model.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2279-87
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17695515-Adenocarcinoma,
pubmed-meshheading:17695515-Animals,
pubmed-meshheading:17695515-Antibodies, Monoclonal,
pubmed-meshheading:17695515-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17695515-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17695515-Breast Neoplasms,
pubmed-meshheading:17695515-Cell Growth Processes,
pubmed-meshheading:17695515-Cell Line, Tumor,
pubmed-meshheading:17695515-Deoxycytidine,
pubmed-meshheading:17695515-Female,
pubmed-meshheading:17695515-Fluorouracil,
pubmed-meshheading:17695515-Humans,
pubmed-meshheading:17695515-Immunohistochemistry,
pubmed-meshheading:17695515-Mice,
pubmed-meshheading:17695515-Mice, Nude,
pubmed-meshheading:17695515-Paclitaxel,
pubmed-meshheading:17695515-Receptors, Estrogen,
pubmed-meshheading:17695515-Xenograft Model Antitumor Assays
|
|
pubmed:articleTitle |
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
|
|
pubmed:affiliation |
Departments of Discovery Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. brian_x.higgins@roche.com
|
|
pubmed:publicationType |
Journal Article
|
